Libtayo is an antibody targeting the immune checkpoint receptor PD-1 and is the only treatment approved in advanced cutaneous squamous cell carcinoma in the European Union, it said.
Price: 315.51, Change: +2.51, Percent Change: +0.80
|Avinger Prices More Than 3.18 Mln Shares at $1.18 Ea...|
|Insiders at Snap (SNAP) Make Significant Stock Sales...|
|AbbVie (ABBV) Insider Makes Significant Share purcha...|
|Insider Sales at Tabula Rasa Healthcare (TRHC) Exten...|
|Goosehead Insurance (GSHD) Insider Makes Significant...|